Tag Archives: NSCLC

B2M Gene Expression Shapes the Immune Landscape of Lung Adenocarcinoma and Determines the Response to Immunotherapy

Scientists performed an integrative analysis of the mutational and transcriptional profiles of large cohorts of non-small-cell lung cancer patients and found that epigenetic downregulation of B2M was common.
[Immunology]
Zhao, Y., Cao, Y., Chen, Y., Wu, L., Hang, H., Jiang, C., & Zhou, X. (n.d.). B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy. Immunology, n/a(n/a). https://doi.org/10.1111/imm.13384 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Imaging CAR T-Cell Kinetics in Solid Tumors: Translational Implications

Scientists conducted dual tumor and T-cell imaging by use of a bioluminescent reporter and positron emission tomography in clinically relevant mouse models of pleural mesothelioma and non-small cell lung cancer.
[Molecular Therapy-Oncolytics]
Skovgard, M. S., Hocine, H. R., Saini, J. K., Moroz, M., Bellis, R. Y., Banerjee, S., Morello, A., Ponomarev, V., Villena-Vargas, J., & Adusumilli, P. S. (2021). Imaging CAR T-Cell Kinetics in Solid Tumors: Translational Implications. Molecular Therapy - Oncolytics, 0(0). https://doi.org/10.1016/j.omto.2021.06.006 Cite
Abstract
Bookmark

No account yet? Register

0
Share

IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Lung Cancer with 43% of Patients Surviving Five Years

Updated results from the positive PACIFIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated a sustained, clinically meaningful overall survival (OS) and progression-free survival (PFS) benefit at five years in patients with unresectable Stage III non-small cell lung cancer (NSCLC) who had not progressed following concurrent chemoradiation therapy (CRT).
[AstraZeneca, Inc. (BusinessWire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

PB01 Suppresses Radio-Resistance by Regulating ATR Signaling in Human Non-Small-Cell Lung Cancer Cells

Scientists reported the antitumor effects and mechanism of a novel benzothiazole derivative 4-methoxy-cyclohexane carboxylic acid [2-(3,5-dimethyl-isoxazole-4-yl) sulpanil-benzothiazole-6-yl]-amide (PB01) in radiation-resistant human non-small-cell lung cancer cells.
[Scientific Reports]
Kim, T. W., Hong, D.-W., & Hong, S. H. (2021). PB01 suppresses radio-resistance by regulating ATR signaling in human non-small-cell lung cancer cells. Scientific Reports, 11(1), 12093. https://doi.org/10.1038/s41598-021-91716-z Cite
Full Article
Bookmark

No account yet? Register

0
Share

Novartis Announces Tabrecta® First Published Overall Survival and Updated Overall Response Data in Patients with METex14 Metastatic NSCLC

Novartis AG has announced the first published mature overall survival and updated overall response rate data following treatment with Tabrecta® in adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14).
[Novartis AG]
Press Release
Bookmark

No account yet? Register

0
Share

Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma

Researchers examined the ability of patient-derived organoids to predict clinical responses to targeted therapies in individual patients and to identify effective anti-cancer therapies for novel molecular targets.
[Clinical Cancer Research]
Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma | Clinical Cancer Research. (n.d.). Retrieved June 4, 2021, from https://clincancerres.aacrjournals.org/content/early/2021/06/03/1078-0432.CCR-20-5026 Cite
Abstract
Bookmark

No account yet? Register

0
Share

FDA Approves Rybrevant for Advanced NSCLC with EGFR Mutations

The FDA granted accelerated approval to amivantamab-vmjw for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
[Clinical Oncology News]
Press Release
Bookmark

No account yet? Register

0
Share

KLHL38 Involvement in Non-Small Cell Lung Cancer Progression via Activation of the Akt Signaling Pathway

Scientists clarified the role of KLHL38 in non-small cell lung cancer (NSCLC). KLHL38 expression was evaluated in tumor and adjacent normal tissues from 241 patients with NSCLC using immunohistochemistry and real-time PCR, and its association with clinicopathological parameters was analyzed.
[Cell Death & Disease]
Xu, Y., Wang, C., Jiang, X., Zhang, Y., Su, H., Jiang, J., Ren, H., & Qiu, X. (2021). KLHL38 involvement in non-small cell lung cancer progression via activation of the Akt signaling pathway. Cell Death & Disease, 12(6), 1–14. https://doi.org/10.1038/s41419-021-03835-0 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Genetic Variants of CHEK1, PRIM2 and CDK6 in the Mitotic Phase-Related Pathway Are Associated with Non-Small Cell Lung Cancer Survival

Reserachers investigated associations between 31,032 single nucleotide polymorphisms (SNPs) in 368 mitotic phase-related pathway genes and overall survival (OS) of patients with non-small cell lung cancer (NSCLC).
[International Journal of Cancer]
Mu, R., Liu, H., Luo, S., Patz, E. F., Glass, C., Su, L., Du, M., Christiani, D. C., Jin, L., & Wei, Q. (n.d.). Genetic variants of CHEK1, PRIM2 and CDK6 in the mitotic phase-related pathway are associated with non-small cell lung cancer survival. International Journal of Cancer, n/a(n/a). https://doi.org/https://doi.org/10.1002/ijc.33702 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Circular RNA circ_0010235 Sponges miR-338-3p to Play Oncogenic Role in Proliferation, Migration and Invasion of Non-Small Cell Lung Cancer Cells through Modulating KIF2A

Researchers intended to investigate role and mechanism of circ_0010235 in non-small-cell lung cancer proliferation, migration and invasion.
[Annals of Medicine]
Molecular Markers and the Promise of Precision Medicine for Interstitial Lung Disease. (2021). Clinics in Chest Medicine, 42(2), 357–364. https://doi.org/10.1016/j.ccm.2021.03.011 Cite
Full Article
Bookmark

No account yet? Register

0
Share

LncRNASGMS1-AS1 Regulates Lung Adenocarcinoma Cell Proliferation, Migration, Invasion, and EMT Progression via miR-106a-5p/MYLI9 Axis

To verify the relationship between SGMS1-AS1, miR-106a-5p, and MYLIP, scientists overexpressed miR-106a-5p inhibitor or MYLIP in lung adenocarcinoma cells after decreasing SGMS1-AS1 and repeated the above assays.
[Thoracic Cancer]
Liu, T., Yang, C., Wang, W., & Liu, C. (n.d.). LncRNA SGMS1-AS1 regulates lung adenocarcinoma cell proliferation, migration, invasion, and EMT progression via miR-106a-5p/MYLI9 axis. Thoracic Cancer, n/a(n/a). https://doi.org/https://doi.org/10.1111/1759-7714.14043 Cite
Full Article
Bookmark

No account yet? Register

0
Share
Share